Medmira (MIR) AI Stock Analysis

• Market Cap: C$45.61M
• Dividend Yield: N/A
• Average Volume (3M): 94.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -41.70%
• EPS Growth: -35.42%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 701,730,600
• 10 Day Avg. Volume: 79,718
• 30 Day Avg. Volume: 94,909
• PEG Ratio: -0.35
• Price to Book (P/B): -2.47
• Price to Sales (P/S): 232.06
• P/FCF Ratio: -17.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.07 ▲(2.86% Upside)

The score is primarily held down by weak financial performance—persistent losses, continued cash burn, and a highly stressed balance sheet with negative equity and elevated leverage. Technicals add pressure with the stock trading below major moving averages and a negative MACD, while valuation provides limited support due to negative earnings and no dividend yield provided.

Positive Factors

Proprietary rapid-test technology

Medmira's proprietary rapid-test technology and point-of-care design create a durable competitive edge: low-equipment, easy-to-use diagnostics are more adoptable in clinics and low-resource settings, enabling licensing, distribution scale and barriers to entry for lesser-developed competitors.

Diversified revenue channels

The firm's mix of product sales, licensing and partnerships, plus government/NGO contracts, provides structurally diversified demand channels. This reduces reliance on a single sales route and supports steady public-health driven demand across regions, improving resilience over months.

Existing commercial traction

Although small, reported TTM product revenue signals real market adoption beyond development-stage activities. Persistent sales validate product-market fit, offering a foundation for scaling, licensing or partnership-led expansion if the company secures the financing to invest in commercialization.

Negative Factors

Severely stressed balance sheet

Negative equity and high debt versus a small asset base materially elevate solvency and refinancing risk. This weak capital structure limits strategic flexibility, increases the likelihood of dilutive financing or asset sales, and constrains the company's ability to fund commercialization or withstand setbacks.

Consistent negative cash flow

Sustained negative operating and free cash flow with worsening FCF increases dependency on external capital. This rising cash burn can force repeated financing rounds, diluting shareholders, or necessitate cost cuts that impair R&D and commercialization, hindering long-term growth prospects.

Deteriorating margins and weak revenue

Margins have moved from positive to sharply negative while revenue remains small and has declined, indicating deteriorating unit economics. Without clear margin recovery or significant revenue scaling, long-term sustainability is at risk and profitability may remain elusive despite operational efforts.

Medmira Business Overview & Revenue Model

Company Description

Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-care testing solutions that enable quick and accurate diagnosis of conditions such as HIV, Hepatitis, and other sexually transmitted infections. Medmira's core product offerings include its proprietary rapid test technologies, which are designed to provide reliable results with minimal equipment and training, catering to both clinical and non-clinical settings worldwide.

How the Company Makes Money

Medmira generates revenue through the sale of its rapid diagnostic tests to healthcare providers, laboratories, and distributors across multiple regions. The company has established key revenue streams that include direct sales of its products, licensing agreements for its technologies, and partnerships with other healthcare organizations to expand its market reach. Additionally, Medmira benefits from contracts with government agencies and non-governmental organizations (NGOs) that require diagnostic testing solutions in various public health initiatives. The company's focus on innovation and the increasing demand for rapid diagnostic solutions in emerging markets further contribute to its financial performance.

Medmira Financial Statement Overview

Summary

Financials are fragile: small and slightly declining revenue, sharply negative and deteriorating margins, and ongoing cash burn. Balance sheet stress is significant with negative equity and high debt relative to assets, increasing solvency/financing risk.

Income Statement

Results show persistent operating losses with deeply negative margins. TTM (Trailing-Twelve-Months) revenue is modest ($0.23M) and slightly down (-3.1%), while profitability deteriorated versus earlier years (gross margin fell from positive levels in 2021–2022 to sharply negative in TTM, and net margin is very negative). A key positive is that revenue is still present, but the overall trajectory points to weakening unit economics and ongoing heavy burn.

Balance Sheet

The balance sheet is highly stressed: stockholders’ equity is negative across all periods (TTM about -$23.4M), indicating accumulated losses and a thin capital cushion. Debt is high relative to the asset base (TTM debt about $17.1M vs. assets about $3.6M), and leverage has increased meaningfully versus prior years. While biotech companies can run with losses during development, the combination of negative equity and rising debt materially elevates financial risk.

Cash Flow

Cash generation remains weak with consistently negative operating cash flow and free cash flow (TTM operating cash flow about -$2.4M; free cash flow about -$2.4M). Free cash flow worsened in TTM (down ~23.6%), signaling increasing cash burn. A relative positive is that free cash flow broadly tracks net loss (loss-driven burn rather than large non-cash distortions), but the company still appears dependent on external financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	240.51K	412.57K	432.53K	952.13K	2.14M
Gross Profit	-990.25K	226.49K	-434.91K	304.03K	1.72M
EBITDA	-3.13M	-2.13M	-1.58M	-1.07M	185.30K
Net Income	-4.52M	-3.33M	-2.68M	-1.83M	-675.80K
Balance Sheet
Total Assets	3.68M	6.07M	3.65M	3.83M	3.89M
Cash, Cash Equivalents and Short-Term Investments	14.91K	2.10M	13.18K	33.46K	-2.30M
Total Debt	10.71M	9.56M	9.27M	8.30M	11.54M
Total Liabilities	26.24M	24.11M	18.68M	16.19M	19.61M
Stockholders Equity	-22.56M	-18.04M	-15.03M	-12.36M	-15.72M
Cash Flow
Free Cash Flow	-3.15M	-3.68M	-1.27M	-1.95M	-541.19K
Operating Cash Flow	-3.15M	-2.94M	-1.27M	-1.88M	-504.64K
Investing Cash Flow	-7.47K	-742.53K	-1.27K	-69.72K	-36.55K
Financing Cash Flow	1.07M	5.77M	1.25M	1.99M	139.32K

Medmira Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	53 Neutral	C$45.02M	21.44	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$31.23M	-15.19	-8.01%	―	-26.81%	-161.24%
DTC	45 Neutral	C$32.29M	-8.33	―	―	―	72.92%
SVA	44 Neutral	C$52.19M	-3.24	―	―	―	54.38%
MIR	42 Neutral	C$45.61M	-10.34	―	―	-41.70%	-35.42%

Medmira Corporate Events

MedMira Narrows Loss as New Syphilis Test Wins Approval and MiROQ Platform Advances

MedMira reported first-quarter fiscal 2026 results marked by Health Canada approval of its Reveal TP rapid syphilis antibody test, enabling nationwide deployment through provincial validations and complementing its existing HIV and dual HIV/TP products. The company advanced its Multiplo Complete Syphilis (TP/nTP) Antibody Test program, moving into a second phase of Canadian clinical trials following strong sensitivity and specificity data published in BMC Infectious Diseases, positioning the test as a tool to support antimicrobial stewardship and reduce healthcare costs. In parallel, MedMira is working with partners to accelerate commercialization of its MiROQ quantitative diagnostic platform, integrating AI for faster, more reliable diagnostics and broadening its future product and market reach. Financially, the quarter showed modest revenue of $54,208 and a narrowed net loss of $813,134 versus the prior year, driven largely by lower operating expenses, alongside a slight decline in assets and an increase in liabilities, underscoring the company’s continued investment phase in product development and regulatory advancement.

The most recent analyst rating on (TSE:MIR) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on Medmira stock, see the TSE:MIR Stock Forecast page.

MedMira Inc. Reports FY2025 Financial Results and Strategic Developments

MedMira Inc. reported its FY2025 financial results, highlighting significant product launches and regulatory approvals in Canada and the USA. Despite a net loss and increased operating expenses due to R&D and marketing activities, the company achieved milestones such as Health Canada approvals and VA and Federal listings in the USA, enhancing its market positioning and sales capabilities. The development of its MiRO Q technology, aimed at improving diagnostics, particularly in cancer, is expected to expand product offerings and market access, providing substantial value to the company.